Connect with us

NEWS

Vitroscope Raises $7 Million to Turn Tissue Into Data

Vitroscope raised $7 million to sell a perfusion box that records living human tissue over days, the data investors want for AI drug discovery.

Published

on

Vitroscope raised $7 million on November 3, 2026, to sell a benchtop system that keeps living human tissue under flow for days. The Trondheim company split the money into a $5 million seed co-led by Cerberus Ventures and YZR Capital and $2 million from the Research Council of Norway.

Backers talk about hardware. They are paying for a clock. Static well plates still dominate drug screens, and they starve complex models of flow and oxygen. vitro.alive is meant to keep those models alive long enough to record how they change, then store that record.

Cerberus and YZR Back a Six-Channel Incubator

Vitroscope AS is based at Krambugata 2 in Trondheim. It was formed in 2019. Co-founders Carlo Kriesi and Heikki Sjöman went full time only in 2021, after sharing an office as friends. The firm has now raised $8.8 million in all.

The equity round also drew Arcas Ventures, Golden Egg Check, Devico Invest, and angels Carles Reina, Fàtima Godall, and Oskari Pétas. The grant sits beside that equity, not inside it. Money from this package is earmarked for selling vitro.alive and for proving vitro.scale, a higher-throughput plate still in development.

THE NOVEMBER 3 PACKAGE

Source Type Amount
Cerberus Ventures and YZR Capital, with Arcas Ventures, Golden Egg Check, Devico Invest, and named angels Seed equity $5 million
Research Council of Norway Non-dilutive grant $2 million
This package Combined $7 million
All funding to date Company total $8.8 million

Kriesi, the CEO, put the product in one line. “We started Vitroscope because living tissue cannot be reduced to a snapshot. Its behaviour depends on what is happening around it over time.” He said the new capital takes that setup into more labs and toward higher-throughput runs on vitro.scale.

The Data Compounds After Every Experiment

Chenny Zhang, managing director at Cerberus Ventures, said biology is not static and much of the way labs still study it is. In her account, watching tissue over time yields rich, longitudinal records that grow more useful as drug work leans on AI.

Markus Feuerecker, founding and managing partner at YZR Capital in Munich, went further. He treated the box as a source of training material, not a one-off instrument sale.

Drug discovery and development need data that allows researchers to actually predict how patients will respond, and Vitroscope generates it at the source. Its platform is physical AI infrastructure: every experiment on living human tissue produces proprietary, comparable data that compounds over time.

Markus Feuerecker, Founding and Managing Partner, YZR Capital

That is the second product hiding inside the first. Each run is supposed to leave a dated, comparable file: images, oxygen, pH, temperature, and flow, captured while the sample is still alive. If labs adopt the same plate, those files stack. If they do not, Vitroscope is another niche incubator with a long service list.

Reina, who joined as an angel after meeting Sjöman in Finland in summer 2026, described the same idea in plainer words. The platform extends the life of human tissue outside the body so scientists can try therapies on it. Time in culture is the scarce input. The round buys more of it.

How Vitro.alive Fits a Standard Microscope

vitro.alive is a closed-loop incubator the size of a standard well plate, with six fully independent perfusion channels, an integrated pump, heating, and gas control. It sits on a normal inverted microscope. Users keep the tissue models they already have. No stage-top incubator is required. The glass bottom is specified for imaging, and the software timestamps every frame.

The company is explicit about what it will not ship. It does not sell a house organoid or a locked chip. It sells flow, sensing, and a browser console for protocols, remote control, alerts, and charts. The stack is end-to-end encrypted and API-based, which is how a physical plate becomes a file other tools can read.

WHAT THE BENCHTOP UNIT DOES

  • Six channels: Each lane runs its own perfusion protocol so six samples can diverge in the same session.
  • Plate footprint: The closed-loop incubator matches a standard well plate and carries its own pump and heaters.
  • Imaging under flow: A 1.5H glass bottom works with inverted microscopes and does not need a stage-top incubator.
  • Browser controls: Protocols, scheduling, alerts, and charts sit in a cloud console with an encrypted API.
  • Sample types: The same hardware is listed for tissue slices, 2D cultures, mechanobiology work, organoids, and 3D bioprints.

On the marketing site, ex vivo slices that still hold immune cells are said to keep 90% viability for days. That figure is the company’s own. It is also the whole commercial claim in miniature: more hours of usable tissue from samples that are hard to get.

Seven Days Inside a Vascularized Brain Organoid

The cleanest public specimen is a 2025 white paper with CONDUCTink Inc. in New Jersey. Using vitro.alive, the groups reported seven-day perfusion of vascularized brain organoids at 37°C and 5% CO2. They drove 2.1 µm green fluorescent beads through CD31-positive vessels, watched them on live fluorescence, and, after clearing, found the beads still inside those vessels. Flow held without leakage or torn tissue, the paper says. The authors called it a first scalable demonstration of true intraluminal flow in an intact vascularized organoid. That is their claim, not a regulator’s.

A separate customer paper in the Journal of the American Society of Nephrology in 2025 used the hardware on kidney work. S. Lindfors, C. Schmotz and colleagues studied glomerular injury after AdipoR1 depletion, looking at how the adiponectin receptor 1 in type 2 diabetes lines up with podocyte loss. Vitroscope did not co-author it. That independence is the point: someone else’s lab could load the plate and publish.

Company materials also say primary human liver cells formed organised tissue on the platform and did not do so in standard well plates. That comparison has not been tied to a named journal article in the public list. Treat it as the vendor’s account until a paper lands.

THE PUBLIC RECORD ON THE HARDWARE

  1. 2019: Vitroscope is formed in Trondheim. Kriesi and University of Zurich colleagues publish the original flow chamber in Frontiers in Bioengineering and Biotechnology, with imaging, biocompatibility, and bench tests.
  2. 2020: A Research Council FORNY project under Kriesi nationalises patent filings in the EU, US, Canada, Korea, Singapore, Australia, China, and Japan, and pays for design work ahead of production.
  3. 2021: Kriesi and Sjöman leave the side-project phase and work full time.
  4. 2024: Julia Schüler of Charles River Laboratories co-authors a Communications Biology paper with Sjöman and Kriesi on sensor-extended imaging for fit-for-purpose cell models.
  5. 2025: The CONDUCTink white paper, the JASN kidney paper, and an MPS Summit poster with SINTEF on shear stress in non-small cell lung cancer cultures all use the platform.
  6. November 3, 2026: The $7 million package is announced to sell vitro.alive and to validate vitro.scale.

Sandra Jernström, listed as CBDO and a late co-founder, is on the organoid white paper. She previously co-founded Okomera and was its CSO. Engineering lead Tor Henry Dyer and scientific lead Vendela Schjetne round out the named staff on the company site. Advisers include Schüler, Emerald Cloud Lab chief DJ Kleinbaum, Oxford’s Marco Fritzsche, and Darryl Kirsh of Fiddlehead Ventures.

A Permanent FDA Path for Tissue Chips

None of that puts Vitroscope on a U.S. qualification list. It does put the firm in a market where the U.S. Food and Drug Administration has already opened a door. The agency’s ISTAND program, launched in November 2020 as a pilot, now sits as a permanent Drug Development Tool path. Among the examples it will consider are tissue chips to assess safety or efficacy.

During the pilot, FDA staff said ISTAND took eight submissions: three AI tools, two methods that assess preclinical safety without animals, two novel methods involving tissues, and one statistical approach. On September 24, 2024, the agency accepted the first letter of intent for an organ-on-a-chip tool, Emulate’s human Liver-Chip, aimed at drug-induced liver injury. That is step one of three. Qualification is still ahead.

The installed alternatives are also larger than a Trondheim seed. MIMETAS sells an OrganoPlate in 40 to 96 culture formats that use gravity-driven flow on a rocker, a high-count layout that fits plate robots. Bruker took a majority stake in MIMETAS in August 2026. Emulate’s workstation is built around a smaller number of more complex chips and a closed instrument. CN Bio and others sell liver-heavy plates of their own.

Vitroscope is trying a different seam. It wants researchers to bring whatever model they already trust, drop it on a microscope they already own, and add pumped flow with imaging. That is easier to try than a full organ-chip stack. It is also easier to ignore. Gravity plates already offer 96 parallel wells. FDA attention is already on named chips with years of DILI data. A six-channel box has to win on the quality of the time series, not on count.

Vitroscope Plans Vitro.scale Customer Tests in 2027

vitro.scale is the answer the company gives to that count problem. It is designed for 96 parallel experiments. Customer testing is expected in 2027. A launch is planned in 2028. Until then, the commercial object is the six-channel unit.

The Research Council already has a 2025 to 2029 Inno-naering project on that scale-up, led by Dyer. The public write-up is blunt about why the work exists. Cell tests are supposed to forecast how a drug will act in a person, and more than 90% of drug programs fail once they reach patients, in part because the cells sat in a non-human setting. The same record describes today’s product as a single-use plate that holds the cells plus a reusable box that runs flow, temperature, gas, and data capture. The next job is miniaturisation and automation without losing the biology already shown at six wells.

THE SCALE-UP CLOCK

  • Now: Sell vitro.alive, six independent lanes, microscope-compatible.
  • 2025 to 2029: National Inno-naering project on industrial throughput.
  • 2027: Expected customer testing of vitro.scale.
  • 2028: Planned launch at 96 parallel experiments.

That calendar is long for a seed story and short for a lab standard. If the six-channel plate does not become common in 2026 and 2027, the 96-well version arrives as another prototype in a field that already has 96-well flow. If it does become common, Feuerecker’s compounding files have somewhere to live.

The $7 million is enough to put vitro.alive on more benches and to build the 96-well test articles. It is not enough, on its face, to outspend organ-chip groups that already sit in FDA queues. The wager is narrower. Keep other people’s tissue alive for days, write down what it does, and hope those notes are what drug models need before the first patient is dosed.

Frequently Asked Questions

Who founded Vitroscope and when did the company go full time?

Carlo Kriesi, a mechanical engineer from ETH Zurich with a PhD from NTNU Trondheim and earlier stints at CORE in Vancouver and at CERN, co-founded the firm with Heikki Sjöman, a mechatronics PhD from NTNU who studied at Aalto and Stanford. They incorporated in 2019 and only started working on it full time in 2021, after sharing an office as friends.

How is the vitro.scale hardware split between plate and box?

The Research Council project describes a single-use plate that holds the cell models and a reusable control unit that runs fluid flow, temperature, gas mix, and data collection, the same split already used at six lanes and the one the 96-lane version is supposed to keep as it shrinks and automates.

Where did Vitroscope nationalise its early patents?

A 2020 Research Council FORNY project, awarded NOK 0.50 million and led by Kriesi, records national filings in the EU, the United States, Canada, Korea, Singapore, Australia, China, and Japan, on top of the company’s later statement that it holds multiple international patents on the core methods.

How many tools did FDA take into ISTAND during the pilot?

FDA staff said the pilot accepted eight submissions in all, made up of three AI-based tools, two tools that assess preclinical safety without animals, two novel methods involving tissues, and one novel statistical approach, before the program was converted from a pilot into a permanent qualification path.

Disclaimer: This article is news reporting on a private company’s funding and laboratory tools, and it is for information only. It is not investment advice, not an offer to buy or sell securities, and not medical or scientific advice about any drug, device, or treatment. Readers who are weighing a financial decision should speak with a licensed financial adviser, and readers who are weighing a laboratory or clinical decision should speak with a qualified scientist or physician. Figures, product plans, and regulatory statuses reflect the company, investor, and agency materials cited here as of the dates on those materials and can change.

Harry is the editor of IAQABA, an independent publication he owns and runs. A decade in journalism, beginning as a reporter and now as the editor of his own titles, has left him with a clear test for what deserves a story: it has to change what a reader knows or decides, and it has to rest on something he can point to. That rules out recycled press releases, forecasts with no data behind them and rumours that no document supports. It leaves room for a great deal, and the site covers news, business, science and technology alongside sports, entertainment and lifestyle, with travel, auto and gaming given the same standard rather than lighter treatment. Sources are primary wherever possible: the regulator's filing, the company's own statement, the transcript, the dataset, or the product on Harry's desk. Figures are checked before they are published and rechecked if a reader questions them. Mistakes are corrected under a published policy. Readers across the world can reach him directly at support@iaqaba.com.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending